1
Abou-Alfa, G. K., Qin, S., Ryoo, B. Y., Lu, S. N., Yen, C. J., Feng, Y. H., . . . Chen, L. T. (2018). Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol, 29(6), 1402-1408. doi: 10.1093/annonc/mdy101 (I.F. 13.926)
2
Agarwal, Kosh, Brunetto, Maurizia, Seto, Wai Kay, Lim, Young-Suk, Fung, Scott, Marcellin, Patrick, . . . Bae, Ho. (2018). 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of hepatology, 68(4), 672-681. (I.F. 14.911)
3
Chang, C. J., Chen, C. H., Chen, B. M., Su, Y. C., Chen, Y. T., Hershfield, M. S., . . . Wu, J. Y. (2017). A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nat Commun, 8(1), 522. doi: 10.1038/s41467-017-00622-4 (I.F. 12.124)
4
Dai, C. Y., Chuang, W. L., & Yu, M. L. (2014). A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C. Hepatology, 60(6), 2128-2129. doi: 10.1002/hep.27096 (I.F.11.190)
5
Kuo, S. H., Chen, L. T., Lin, C. W., Yeh, K. H., Shun, C. T., Tzeng, Y. S., . . . Cheng, A. L. (2017). Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. Blood, 129(2), 188-198. doi: 10.1182/blood-2016-04-713719 (I.F. 13.164)
6
Liu, C. J., Chuang, W. L., Sheen, I. S., Wang, H. Y., Chen, C. Y., Tseng, K. C., . . . Chen, P. J. (2018). Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology, 154(4), 989-997. doi: 10.1053/j.gastro.2017.11.011 (I.F. 20.773)
7
Su, Y. C., Burnouf, P. A., Chuang, K. H., Chen, B. M., Cheng, T. L., & Roffler, S. R. (2017). Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nat Commun, 8, 15507. doi: 10.1038/ncomms15507 (I.F. 12.124)
8
Tsai, P. C., Huang, C. F., & Yu, M. L. (2017). Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy. Journal of Hepatology, 66(2), 464-464. doi: DOI 10.1016/j.jhep.2016.10.035 (I.F. 12.486)
9
Wang, C. Y., Wong, W. W., Tsai, H. C., Chen, Y. H., Kuo, B. S., Lynn, S., . . . Liao, M. J. (2019). Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. N Engl J Med, 380(16), 1535-1545. doi: 10.1056/NEJMoa1802264 (I.F. 70.670)
10
Yen, Yung-Feng, Chuang, Pei-Hung, Jen, I-An, Chen, Marcelo, Lan, Yu-Ching, Liu, Yen-Ling, . . . Chen, Yi-Ming Arthur. (2017). Incidence of autoimmune diseases in a nationwide HIV/AIDS patient cohort in Taiwan, 2000–2012. Annals of the rheumatic diseases, 76(4), 661-665. (I.F. 12.811)